Azenta Inc (AZTA)vsWest Pharmaceutical Services Inc (WST)
AZTA
Azenta Inc
$31.82
+5.61%
HEALTHCARE · Cap: $1.30B
WST
West Pharmaceutical Services Inc
$351.02
+0.65%
HEALTHCARE · Cap: $24.00B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 458% more annual revenue ($3.33B vs $596.48M). WST leads profitability with a 17.0% profit margin vs -29.1%. AZTA appears more attractively valued with a PEG of 0.53. WST earns a higher WallStSmart Score of 61/100 (C+).
AZTA
Buy53
out of 100
Grade: C-
WST
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+30.3%
Fair Value
$43.66
Current Price
$31.82
$11.84 discount
Margin of Safety
-47.9%
Fair Value
$166.45
Current Price
$351.02
$184.57 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
1.0% revenue growth
Smaller company, higher risk/reward
ROE of -11.5% — below average capital efficiency
Currently unprofitable
Trading at 8.3x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : AZTA
The primary concerns for AZTA are Revenue Growth, Market Cap, Return on Equity.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while WST is a mature play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.37 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
WST generates stronger free cash flow (81M), providing more financial flexibility.
Bottom Line
WST scores higher overall (61/100 vs 53/100), backed by strong 17.0% margins and 13.8% revenue growth. AZTA offers better value entry with a 30.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?